Skip to main content
Fig. 5 | Molecular Medicine

Fig. 5

From: Antibody-drug conjugates targeting CD248 inhibits liver fibrosis through specific killing on myofibroblasts

Fig. 5

IgG78-DM1 could prevent liver fibrosis in CCl4-induced mice. A Schematic of the experimental design for the establishment and treatment of CCl4-induced mice. B IF staining showing the localization of IgG78-DM1 in the liver tissue of CCl4-induced mice. C Sirius Red staining showing that IgG78-DM1 could alleviate liver fibrosis in CCl4-induced mice (n = 5). D Quantification of the data in C. E Ishak score of the liver tissue. F The hepatic hydroxyproline content after treatment. G Serum levels of ALT after treatment (n = 5 in BG). H qRT-PCR to show the mRNA levels of Cd248 and fibrosis-related genes (Acta2, Col1a1, Tgfbr1 and Pdgfrα) in the liver tissues. I Western blotting showing the protein levels of α-SMA, collagen, and CD248 in liver tissues. J TUNEL staining showing the apoptosis of α-SMA-positive HSCs in liver tissues. K Quantification of the data in J (n = 3 in HK). Representative images are shown. Scale bar, 100 μm, **p < 0.01, *** p < 0.001, ****p < 0.0001. DM1 Mertansine, HSC hepatic stellate cell, IF immunofluorescence, ALT alanine aminotransferase, qRT-PCR quantitative real-time reverse transcription polymerase chain reaction, α-SMA alpha smooth muscle actin, TUNEL terminal deoxynulceotidyl transferase nick-end-labeling

Back to article page